Association between nociplastic pain and premature endocrine therapy discontinuation in breast cancer patients

Purpose At least 5 years of adjuvant endocrine therapy (ET) is recommended for patients with hormone receptor-positive invasive breast cancer to reduce cancer recurrence risk. Up to half of patients prematurely discontinue ET, often due to musculoskeletal pain. Nociplastic pain is abnormal central n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2023-01, Vol.197 (2), p.397-404
Hauptverfasser:	Joyce, Elizabeth, Carr, Grant, Wang, Sidi, Brummett, Chad M., Kidwell, Kelley M., Henry, N. Lynn
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant treatment Analysis Antineoplastic Agents, Hormonal - adverse effects Aromatase Inhibitors - adverse effects Breast cancer Breast Neoplasms - chemically induced Breast Neoplasms - complications Breast Neoplasms - drug therapy Cancer Cancer patients Cancer research Care and treatment Central nervous system Chemotherapy, Adjuvant - adverse effects Cohort Studies Endocrine therapy Epidemiology Female Fibromyalgia Fibromyalgia - chemically induced Fibromyalgia - complications Fibromyalgia - drug therapy Health aspects Humans Invasiveness Male Medical records Medicine Medicine & Public Health Musculoskeletal Pain - chemically induced Neoplasm Recurrence, Local - drug therapy Oncology Oncology, Experimental Pain Patients Prevention Quality of Life Retrospective Studies Surgery Women
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!